Norway’s Lytix Biopharmahas come out of stealth mode and landed its first commercial deal by licensing lead asset LTX-315 to US-based Verrica Pharmaceuticals, Inc., which will now develop and commercialize it for dermatologic oncology indications.
Norway’s Lytix Licenses Lead Asset To Verrica For Skin Cancers
CEO Tells Scrip Licensing Pact Is Its First, But Not Last
Norwegian biotech Lytix says a licensing deal with Verrica in dermatologic oncology indications gives it commercial validity – and leaves options open in other cancer areas.
